Search clinical trials for: 5-aza-cytidine and Thalidomide

Total 9222 results

Tel-Aviv Sourasky Medical Center

Unknown

Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) (IMDS001)

Myelodysplastic Syndrome

Israel
M.D. Anderson Cancer Center

Completed

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Leukemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Leukemia | AML | MDS

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes | Myeloproliferative Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; Celgene Corporation

Completed

PKC412 and 5-Azacytidine

Leukemia

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
Zhujiang Hospital

Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute

China
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Refractory Acute Leukemia | Pediatric Relapsed

United States
M.D. Anderson Cancer Center

Completed

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Colorectal Cancer

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
HiberCell, Inc.

Recruiting

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Leukemia

United States
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
Fred Hutchinson Cancer Center

Completed

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
The University of Texas Health Science Center,...

Recruiting

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma (5-AZA)

Recurrent Ependymoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Biphenotypic Leukemia

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease

Fibrosis | Chronic Liver Disease

Taiwan
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
University of Leipzig
AbbVie; University Hospital Leipzig, Hematology Diagnostics Laboratory; University...

Recruiting

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute Myeloid Leukemia (AML)

Germany
University of Pittsburgh

Withdrawn

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (UPCI 13-165)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Advanced Cancers

United States
M.D. Anderson Cancer Center
Seagen Inc.

Terminated

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
M.D. Anderson Cancer Center
Yukiguni Maitake Company Ltd.

Terminated

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Advanced Cancers

United States
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Washington University School of Medicine

Completed

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris

Acne Vulgaris

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States, Israel, India
Shirley Ryan AbilityLab
Rady Children's Hospital, San Diego

Not yet recruiting

Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy

Cerebral Palsy | Contracture
The First Affiliated Hospital of Soochow University

Recruiting

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Acute Myeloid Leukemia

China
Roswell Park Cancer Institute
National Cancer Institute (NCI); Teva Pharmaceutical Industries, Ltd.

Terminated

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
University of Hawaii
SBI ALApromo Co., Ltd. - Strategic Business Innovator

Completed

Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood

Stress | Insomnia | Irritability | Coping Behavior | Nocturnal Awakening

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Solid Tumors

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase II 5-Azacytidine Plus VPA Plus ATRA

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia... and other conditions

United States

Search clinical trials for: 5-aza-cytidine and Thalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations